Brief: Simulations Plus Enters New Strategic Collaboration To Discover Anticancer Therapies Through Its Ai-Driven Drug Design Technology
28/03/2023 13:39
March 28 (Reuters) - Simulations Plus Inc SLP.O :
* SIMULATIONS PLUS ENTERS NEW STRATEGIC COLLABORATION TO
DISCOVER
ANTICANCER THERAPIES THROUGH ITS AI-DRIVEN DRUG DESIGN
TECHNOLOGY
* SIMULATIONS PLUS - PER TERMS OF COLLABORATION, CO TO
DEVELOP
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP (QSAR) MODELS FOR
EFFICACY AGAINST MTHFD2
Source text for Eikon: ID:nBw4V76Z6a
Further company coverage: SLP.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Simulations Plus
See all newsBrief: Simulations Plus Altaris To Pay $26 Million Termination Fee To Co If Merger Agreement Terminated
NASDAQ RESUMED AT 09:55 AM
Brief: Simulations Plus To Be Acquired By Altaris For Approximately $375 Million
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:55 AM
Simulations Plus Q2 results beat expectations but lowers annual profit forecast on tax rate jump